Jørn Herrstedt1, Fausto Roila2, David Warr3, Luigi Celio4, Rudolph M Navari5, Paul J Hesketh6, Alexandre Chan7, Matti S Aapro8. 1. Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 C, Odense, Denmark. herrstedt@rsyd.dk. 2. Santa Maria Hospital, Terni, Italy. 3. Princess Margaret Cancer Center, Toronto, ON, Canada. 4. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. 5. Indiana University School of Medicine, South Bend, IN, USA. 6. Lahey Hospital & Medical Center, Burlington, NJ, USA. 7. National University of Singapore, Singapore City, Singapore. 8. Clinique de Genolier, Genolier, Switzerland.
Abstract
PURPOSE: This review summarizes the recommendations for the prophylaxis of nausea and vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1500 mg/m2, carmustine, dacarbazine, and the combination of an anthracycline and cyclophosphamide (AC) administered to women with breast cancer, as agreed at the MASCC/ESMO Antiemetic Guidelines Update meeting in Copenhagen in June 2015. METHODS: A systematic review of the literature using PubMed and the Cochrane Database from 2009 to June 2015 was performed. RESULTS: The NK1-receptor antagonists netupitant (300 mg given in combination with palonosetron 0.5 mg as NEPA) and rolapitant have both completed phase II and III programs and were approved by FDA (both) and EMA (NEPA) in 2014-2015. Addition of one of these agents (or of (fos)aprepitant) to a combination of a serotonin (5-HT)3-receptor antagonist and dexamethasone improved the number of patients with a complete response (no emesis and no rescue medication) days 1-5 after AC HEC with 8-9 % and after non-AC HEC by 8-20 %. Olanzapine has improved control of delayed nausea as compared to aprepitant in a randomized open designed study. In the prophylaxis of delayed nausea and vomiting, metoclopramide is an option instead of aprepitant in patients receiving cisplatin-based chemotherapy and dexamethasone is an option instead of aprepitant in patients receiving AC chemotherapy. CONCLUSIONS: Two new NK1-receptor antagonists (netupitant and rolapitant) have been included in the updated recommendations as additional options to aprepitant or fosaprepitant. Addition of one of these NK1-receptor antagonists to a combination of a 5-HT3-receptor antagonist and dexamethasone is recommended in both non-AC HEC and AC HEC. Olanzapine is included as an option in HEC in particular if nausea is the main symptom.
PURPOSE: This review summarizes the recommendations for the prophylaxis of nausea and vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1500 mg/m2, carmustine, dacarbazine, and the combination of an anthracycline and cyclophosphamide (AC) administered to women with breast cancer, as agreed at the MASCC/ESMO Antiemetic Guidelines Update meeting in Copenhagen in June 2015. METHODS: A systematic review of the literature using PubMed and the Cochrane Database from 2009 to June 2015 was performed. RESULTS: The NK1-receptor antagonists netupitant (300 mg given in combination with palonosetron 0.5 mg as NEPA) and rolapitant have both completed phase II and III programs and were approved by FDA (both) and EMA (NEPA) in 2014-2015. Addition of one of these agents (or of (fos)aprepitant) to a combination of a serotonin (5-HT)3-receptor antagonist and dexamethasone improved the number of patients with a complete response (no emesis and no rescue medication) days 1-5 after AC HEC with 8-9 % and after non-AC HEC by 8-20 %. Olanzapine has improved control of delayed nausea as compared to aprepitant in a randomized open designed study. In the prophylaxis of delayed nausea and vomiting, metoclopramide is an option instead of aprepitant in patients receiving cisplatin-based chemotherapy and dexamethasone is an option instead of aprepitant in patients receiving AC chemotherapy. CONCLUSIONS: Two new NK1-receptor antagonists (netupitant and rolapitant) have been included in the updated recommendations as additional options to aprepitant or fosaprepitant. Addition of one of these NK1-receptor antagonists to a combination of a 5-HT3-receptor antagonist and dexamethasone is recommended in both non-AC HEC and AC HEC. Olanzapine is included as an option in HEC in particular if nausea is the main symptom.
Authors: F Roila; B Ruggeri; E Ballatori; S Fatigoni; C Caserta; L Licitra; A Mirabile; M T Ionta; B Massidda; L Cavanna; M A Palladino; A Tocci; S Fava; I Colantonio; L Angelelli; L Ciuffreda; G Fasola; F Zerilli Journal: Ann Oncol Date: 2015-03-05 Impact factor: 32.976
Authors: Anup K Majumdar; Jacqueline B McCrea; Deborah L Panebianco; Michael Hesney; James Dru; Marvin Constanzer; Michael R Goldberg; Gail Murphy; Keith M Gottesdiener; Christopher R Lines; Kevin J Petty; Robert A Blum Journal: Clin Pharmacol Ther Date: 2003-08 Impact factor: 6.875
Authors: Steven M Grunberg; Janusz Rolski; Janos Strausz; Zeba Aziz; Stephen Lane; Mark W Russo; Paul Wissel; Mary Guckert; Oliver Wright; Jørn Herrstedt Journal: Lancet Oncol Date: 2009-05-08 Impact factor: 41.316
Authors: Ralph V Boccia; Lucio N Gordan; Gemma Clark; Julian D Howell; Steven M Grunberg Journal: Support Care Cancer Date: 2010-09-12 Impact factor: 3.603
Authors: P J Hesketh; G Rossi; G Rizzi; M Palmas; A Alyasova; I Bondarenko; A Lisyanskaya; R J Gralla Journal: Ann Oncol Date: 2014-03-07 Impact factor: 32.976
Authors: M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg Journal: Ann Oncol Date: 2014-03-05 Impact factor: 32.976
Authors: Angela M Stover; Benjamin Y Urick; Allison M Deal; Randall Teal; Maihan B Vu; Jessica Carda-Auten; Jennifer Jansen; Arlene E Chung; Antonia V Bennett; Anne Chiang; Charles Cleeland; Yehuda Deutsch; Edmund Tai; Dylan Zylla; Loretta A Williams; Collette Pitzen; Claire Snyder; Bryce Reeve; Tenbroeck Smith; Kristen McNiff; David Cella; Michael N Neuss; Robert Miller; Thomas M Atkinson; Patricia A Spears; Mary Lou Smith; Cindy Geoghegan; Ethan M Basch Journal: JCO Oncol Pract Date: 2020-02-19
Authors: Anita R Peoples; Eva Culakova; Charles E Heckler; Michelle Shayne; Tracey L O'Connor; Jeffrey J Kirshner; Peter W Bushunow; Gary R Morrow; Joseph A Roscoe Journal: Support Care Cancer Date: 2019-03-30 Impact factor: 3.603